Our Science
1. Senolytic Drug Discovery
In recent years, aging-related diseases have been increasingly linked to the accumulation of senescent cells. These cells progressively build up in body tissues due to both natural aging and stress-induced premature aging, leading to loss of organ functionality, chronic inflammation, and tumorigenesis. Senolytics offer a promising therapeutic solution by targeting senescent cells without harming healthy ones.
Based on experimental results to date, FlavoLife’s innovative drugs appear to be highly effective and safe senolytics, significantly surpassing current scientific standards.
The goal of FlavoLife is to advance the preclinical development of these drugs, especially for rare disease, paving the way for the execution of regulatory preclinical studies.
2. Medical Food
The innovative senolytic compounds developed by FlavoLife originate from a proprietary platform of small molecules based on a natural flavonoid scaffold. Using a hybrid process combining biology, computational methods, and iterative medicinal chemistry, a library of highly manageable pharmaceutical compounds has been created. These compounds feature an extended therapeutic window up to 500 times the biologically active dose and an estimated toxic dose more than 30 times that of the natural scaffold.